International Journal of Creative and Open Research in Engineering and Management
ISSN: **3108-1754 (Online)**
Volume 02 Issue 04 April-2026 | Impact Factor: 3.5

Optimizing Drug Therapy in Diabetic Nephropathy: A Comprehensive Review

Mr. Shivam Jha[1], Ms. Ritu[2], Jeewanjot singh[3], Abdul Balal[4], Faizan Hassan[5],Priyanshu Raj[6], MD. Anees[7]

Assistant Professor[1], Associate Professor[2], Assistant Professor[3], UG Student[4], UG Student[5], UG Student[6], UG Student[7]

Desh Bhagat University, Mandi Gobindgarh, India, Punjab, 147301, E-mail-shivamjha23@gmail.com

Desh Bhagat University, Mandi Gobindgarh, India, Punjab, 147301, E-mail- Ritu001@gmail.com

Desh Bhagat University, Mandi Gobindgarh, India, Punjab, 147301, E-mail-sandhujeewan7@gmail.com

Desh Bhagat University, Mandi Gobindgarh, India, Punjab, 147301, E-mail-abdulbalal12@gmail.com

Desh Bhagat University, Mandi Gobindgarh, India, Punjab, 147301, E-mail- hassanfaizan021@gmail.com

Desh Bhagat University, Mandi Gobindgarh, India, Punjab, 147301, E-mail- priyanshukumar980157@gmail.com

Desh Bhagat University, Mandi Gobindgarh, India, Punjab, 147301, E-mail- mohdanees705100@gmail.com

How to Cite this Article:

Balal, A., Hassan, F., Raj, P. & Anees, M. (2026). Optimizing Drug Therapy in Diabetic Nephropathy: A Comprehensive Review. International Journal of Creative and Open Research in Engineering and Management, 02(04). https://doi.org/10.55041/ijcope.v2i4.408

https://doi.org/10.55041/ijcope.v2i4.408

Abstract

Diabetic renal failure is a complex metabolic and renal pathology resulting from the interplay of hyperglycemia, hypertension, and chronic kidney disease (CKD). The management of this condition requires a comprehensive understanding of the pathophysiology, pharmacokinetic changes, and current clinical guidelines to ensure safe and effective pharmacotherapy. Renal impairment significantly alters drug absorption, distribution, metabolism, and excretion, necessitating careful dose adjustments to prevent toxicity and maintain therapeutic efficacy. The principles of dose modification involve estimating renal function using eGFR or creatinine clearance, classifying the degree of renal impairment, and applying strategies such as dose reduction, increased dosing interval, or a combination of both. The choice of antidiabetic agents should balance glycemic control and renal safety, with metformin, SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors being preferred options based on the stage of CKD. Insulin therapy requires individualized dosing and close monitoring to avoid hypoglycemia. Managing comorbidities such as hypertension, dyslipidemia, and cardiovascular risk is crucial, with RAAS inhibitors, statins, and antiplatelet agents being key components of the treatment plan. Clinical guidelines from ADA, KDIGO, and EASD provide evidence-based recommendations for personalized therapy, emphasizing the importance of multidisciplinary care, patient education, and regular monitoring of renal function and metabolic parameters. Future directions include the development of novel renoprotective agents, precision medicine approaches, and the integration of digital health technologies to optimize outcomes in this vulnerable patient population.

keywords

Diabetes mellitus, Renal failure, Chronic kidney disease, Pharmacokinetics, Drug dosing, Glomerular filtration rate

1. Introduction

This has made diabetes mellitus to be one of the most serious health problems in the 21 st century, having been estimated to be impairing over half-a-billion individuals globally [1]. Renal failure, especially diabetic nephropathy is one of the most severe and life-threatening complications of it. The prevalence of chronic kidney disease (CKD) in diabetic patients is about 20-40% and thus diabetes is the primary cause of end-stage renal disease (ESRD) in the world [2]. This comorbidity of diabetes and renal impairment is not only harmful and morbid to the patient, but also a significant economic and therapeutic burden to the healthcare systems. Renal dysfunction significantly changes the effects on the body in its capacity to deal with drugs, which causes great changes in the pharmacokinetic pattern of absorption, distribution, metabolism, and excretion [3]. Because the kidneys are important in excretion of most drugs and their metabolites, renal failure may lead to drug retention and toxicity in case of normal doses are taken. Hence, the careful and safe pharmacotherapy using rational dose adjustment is an essential pillar of effective and safe pharmacotherapy in diabetic patients with renal failure. Diabetes on its own makes the process of drug dosing problematic owing to changes in glucose levels, comorbid cardiovascular disorders, polypharmacy (using multiple drugs) [4]. The complexity of dealing with these patients increases when renal failure is incorporated in the equation. An example is that most commonly used oral antidiabetic agents, either metformin or some sulfonylureas, need to be closely monitored or even discontinued with progressive renal failure. In the same way, CKD reduces the insulin clearance, thus in most cases requiring reduced doses of insulin to avoid hypoglycemia [5]. In addition to glycemic control, clinicians should treat hypertension, dyslipidemia, and cardiovascular risk with the pharmacokinetics of which can also change in the state of renal impairment [6]. To achieve rational administration of drug dosing in diabetic renal failure, one needs to have a personal approach based on proper evaluation of renal function, often by use of estimated glomerular filtration rate (eGFR) or creatinine clearance (CrCl). The importance of clinical judgment, revised guidelines, and drug-specific pharmacological knowledge in the prevention of adverse events and optimal therapeutic outcome is all the essential in the field of preventing adverse events and optimizing therapeutic outcomes [7]. Furthermore, the interactions of endocrinologists, nephrologists, and clinical pharmacists are required in order to balance efficacy and safety in such complicated cases. The treatment is characterized by new medications, including SGLT2 inhibitors and GLP-1 receptor agonists, which have both a glycemic and a renal effect on the treatment, bringing an absolute change to the treatment landscape in recent years [8]. Due to the increasing global incidence of diabetes, diabetic renal failure in patients will only increase, which is why there is an urgent need to provide awareness, education, and evidence-based dosing [9]. Altogether, diabetic renal failure is a complicated point of metabolic and renal pathology where the management of medications should be closely considered to achieve positive patient results. The persuasive comprehension of pathophysiology, pharmacokinetics, and prevailing clinical guidelines is essential in giving safe, tailored, and effective care to this susceptible group of people [10].

2. Pathophysiology of Renal Impairment in Diabetic Patients

Diabetic nephropathy or diabetic kidney disease (DKD) is considered among the most common and destructive microvascular complication of both type 1 and diabetes mellitus type 2 [11]. It is a progressive disorder that is expressed by structural and functional changes in the kidneys, which eventually results in chronic kidney disease (CKD) and end-stage renal disease (ESRD) [12]. The pathophysiological processes involved in this condition are essential in the adequate diagnosis and treatment intervention and rational dosage modification of medicines.

2.1 Mechanisms of Diabetic Nephropathy

The diabetic nephropathy pathogenesis is multifactorial, which is characterized by the complex interplay of metabolic, hemodynamic, inflammatory, and genetic factors [13]. Chronic hyperglycemia causes and propagates a series of biochemical and morphological events in renal microvasculature.

2.1.1 Metabolic Factors

Continued hyperglycemia causes non-enzymatic glycation of the proteins to produce advanced glycation end-products (AGEs) [14]. These AGEs become deposited in glomerular basement membrane and mesangial cells leading to thickening and fibrosis.

They also bind to their receptors (RAGE) on the endothelial and inflammatory cells that stimulate oxidative stress and inflammation, which cause additional damage to the renal tissue

2.1.2 Hemodynamic Factors

The overproduction of the vasoactive mediators angiotensin II and endothelin-1 stimulated by hyperglycemia results in glomerular hyperfiltration and elevated intraglomerular pressure [15]. This hyperfiltration is first a compensatory process to excrete surplus glucose but eventually, it will lead to mechanical stress on glomerular capillaries resulting in glomerulosclerosis and proteinuria.

2.1.3 Inflammatory and Oxidative Stress

The elevated levels of glucose stimulate a number of signaling pathways (e.g., protein kinase C, NF-kB) that increase the inflammatory cytokines including TNF-a, IL-6, and TGF-b[16]. These mediators add to the mesangial growth, the extra cellular deposition and the tubular atrophy. Continued production of oxidative stress due to mitochondrial dysfunction and the action of NADPH oxidase also increases the speed of renal injury.

2.1.4 Genetic and Epigenetic Factors

Genetic predisposition is also a factor that defines the type of diabetic patients that form nephropathy [17]. The changes in genes that control renin-angiotensin-aldosterone system (RAAS) antioxidant defense, and inflammatory mechanisms contribute to the development of diseases. Glycemic control can even cause epigenetic alteration of DNA-methylation and histone-modification that can maintain renal damage even after glycemic control is restored, a phenomenon termed as metabolic memory.

2.1.5 Podocyte Injury

The specialized epithelial cells constitute podocytes and they constitute an important segment of glomerular filtration barrier [18]. Podocyte apoptosis and detachment are early processes in diabetes resulting in albuminuria. The destruction of podocytes is frequent and non-reversible and directly proportional to the development of glomerulosclerosis.

Fig.1 Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target

2.2 Structural and Functional Changes in the Diabetic Kidney

The nephropathy of diabetic disease has hallmark pathological characteristics that include: Thickness of glomerular basement membrane (GBM) [19]. Expansion of mesangiole capillaris owing to deposition of extra cellular matrix. Glomerulosclerosis especially nodular (Kimmelstiel-Wilson) lesions. Tubulointerstitial fibrosis, inflammation. Afferent and efferent arteriolar hyalinosis. Such structural alterations lead to smooth deterioration of the glomerular filtration rate (GFR) causing dysfunction of the excretory and regulatory renal functions. The stages of diabetic nephropathy include five stages, beginning with hyperfiltration, through to renal failure.

Fig.2 Changes in the Normal Kidney glomerulus and Diabetic Kidney glomerulus

2.3 Stages of Diabetic Kidney Disease

Stage1.Hyperfiltration Early in the course of diabetes, this stage is marked by renal hypertrophy and elevated GFR. This stage lays the foundation for subsequent harm even though it is asymptomatic [20].Stage2. Normal albuminuria, or the Silent Stage Urinary albumin levels stay normal while structural alterations like mesangial expansion and GBM thickening start to show. Stage3. Microalbuminuria in Stage Three This is the first clinical indication of nephropathy and is identified by urinary albumin excretion of 30–300 mg/day. If blood pressure, cholesterol, and glucose control are optimized, it is a reversible stage [21].Stage4. Overt Nephropathy, or Macroalbuminuria Over 300 mg of albumin are excreted daily, along with edema, hypertension, and a declining GFR. There is clear evidence of progressive renal scarring. Stage5.End stage renal disease. When GFR drops below 15 mL/min/1.73m², dialysis or a kidney transplant are required as forms of renal replacement therapy. Most patients at this stage are at high cardiovascular risk and have several comorbidities [22].

2.4 Progression to Chronic Kidney Disease and Renal Failure

Early nephropathy progresses to CKD and ESRD as a result of several interrelated processes.

Persistent hyperglycemia causes ongoing oxidative and inflammatory stress, which damages the tubules and glomerulus irreversibly.When the RAAS is activated, fibrosis is promoted and intraglomerular pressure increases.Hypertension accelerates nephron loss by raising mechanical stress, whereas dyslipidemia worsens damage by accumulating lipids in renal tissues.Proteinuria itself is a mediator of damage because filtered proteins lead to tubular inflammation and fibrosis.Chronic kidney disease (CKD) is accelerated by smoking, uncontrolled blood pressure, poor glycemic control (HbA1c >8%), and coexisting cardiovascular disease [23]. Acute kidney injury (AKI) may also occur more frequently in diabetic patients, which can accelerate the decline of renal function.

2.5 Clinical Implications

Clinical decision-making requires an understanding of the pathophysiology of diabetic nephropathy, especially when it comes to medication dosage adjustments [24]. As the state of renal function declines:Drugs and their metabolites are not properly excreted, which can result in buildup and toxicity.Hypoalbuminemia may result in decreased plasma protein binding, which would change the concentration of the free (active) medication.The effects of uremic toxins on the liver enzymes and gastrointestinal tract can also alter drug metabolism and absorption.As a result, clinicians need to closely monitor renal function and adjust doses as necessary to maintain therapeutic effectiveness while preventing adverse side effects. In addition, interventions addressing early pathophysiological mechanisms including hyperglycemia management, RAAS inhibition, and reducing oxidative stress may slow disease progression and preserve renal function, simplifying pharmacologic management.

3.Pharmacokinetic Changes in Renal Failure

Renal impairment can significantly impact pharmacokinetics which encompasses the absorption, distribution, metabolism, and excretion (ADME) of medications [15]. For example, urinary pharmacokinetic alterations in patients with diabetes that confers renal failure become especially clinically pertinent, as the kidney is a major host organ of drug elimination and homeostasis. Consequently, not recognizing drug pharmacokinetics in this cohort of patients can cause either insufficient therapeutic effects, drug accumulation, or toxicities with life-threatening consequences. Therefore, we must understand pharmacokinetic changes in order to optimize therapeutic regimens and provide an appropriate rationale for adjusting drug dosing in this patient population.

3.1 Altered Drug Absorption

Altered absorption of drug can arise from various renal physiology mechanisms due to renal failure. Uremic solvents that occur in advanced renal disease lead to gastrointestinal (GI) disturbances including nausea, vomiting, delayed gastric emptying, and bowel edema, all of which contribute to impaired absorption of orally administered drugs. In addition, diabetic gastroparesis, which is also a common comorbid condition in this age group, will contribute to decrease gastric emptying, causing unpredictable plasma concentrations of drug.

Additionally, alteration in gastric pH due to increased ammonia production and modification of acid secretion under uremic condition can modify the solubility and ionization of weakly acidic or weakly basic drugs. For example, absorption of drugs, such as furosemide or ferrous sulfate, is reduced under uremic conditions. Similarly, phosphate binders, calcium supplements, and antacids now commonly prescribed to patient with chronic kidney disease (CKD) can bind either to prevent solubility or form insoluble complexes with antibiotics or antidiabetic Agents further decreasing bioavailability.Lastly, activity of intestinal drug transporters (eg, P-glycoprotein and others) and metabolic enzymes (eg, CYP3A4) are effectively inhibited by uremic solvents leading to reduced first-pass metabolism of the drug and unexpected higher systemic exposure to orally administered drugs [25].

3.2 Alterations in Drug Distribution

Drug distribution in the body is influenced by plasma protein binding, tissue permeability, and body composition, all of which are altered in renal failure [26].

1.Protein Binding: In uremia, plasma protein levels, especially albumin, and binding capacity are decreased, and the higher concentrations of organic acids and toxins will compete with drugs for albumin's binding sites. The result is an increased free (unbound) fraction of drugs, such as phenytoin, valproic acid, and warfarin, that have a protein-binding value. The higher free concentration may improve pharmacologic activity but also contributes to higher toxicity. In addition, in diabetic nephropathy, the added effects of metabolic acidosis and frequently occurring hypoalbuminemia could further increase the variable free fraction of drug activity.

2. Altered Tissue Binding. Certain drugs will be distributed throughout tissues based on the pH and ionic gradients across membranes in the vascular/cellular compartments. Renal failure alters these gradients, which may impact the resultant Vd of the drug. Lipophilic drugs may demonstrate increased Vd due to expanded extracellular fluid, and hydrophilic agents may demonstrate decreased tissue penetration.

3. Changes in body composition. Fluid overload and edema associated with CKD may increase the extracellular compartment and affect the

hospitals' distribution (Vd) for water-soluble drugs (e.g., aminoglycosides, insulin). Muscle wasting, on the other hand, may decrease total body stores of creatinine and result in a potentially greater overestimation of kidney function. This increases complexity when dose adjustments are indicated. Together, these distributional changes require careful interpretation of plasma drug concentrations and further highlight the need for therapeutic drug monitoring (TDM) of renally impaired patients.

3.3 Changes in Drug Metabolism

The liver continues to be the primary site of drug metabolism, but renal impairment has a significant impact on drug metabolism that is not related to renal clearance. In favorable cases of impaired renal function, the cycling of substance metabolism (e.g., beta-blockers, opioids, and select oral hypoglycemics) could be subsequently decreased because uremic toxins can inhibit hepatic cytochrome P450 (CYP) enzymes (such as CYP3A4, CYP2C9, and CYP2D6) [27].

Also, drug-metabolizing enzymes and transporters local to the kidney (e.g., CYP450 isoenzymes, UDP-glucuronosyltransferases, and organic anion/cation transporters) will also become down-regulated during renal failure, restricting phase I (e.g., oxidation or reduction) and phase II (conjugation) reactions. Thus, medications predominantly metabolized hepatically may also have an extended half-life and require dosage adjustments in CKD.

For example:Insulin will experience an inadequate degradation from the decreased renal metabolism, predisposing the patient to hypoglycemic complications.Morphine and its active metabolite (morphine-6-glucuronide) will accumulate in renal failure and cause central nervous system depression.Sulfonylureas (especially glyburide) will also continue to exert increased duration of action and hypoglycemic effect after administration from the delayed clearance of active metabolites.Therefore, renal failure can indirectly impair hepatic and renal metabolic pathways, thus relying on ongoing clinical monitoring

3.4 Reduced Drug Excretion

1. The kidney is the principal organ for the excretion of many drugs and metabolites through three primary mechanisms: glomerular filtration, tubular secretion, and tubular reabsorption. These three mechanisms are also significantly impaired in renal failure [28].2.Diminished Glomerular Filtration Rate (GFR) In chronic kidney disease (CKD), the GFR declines in proportion to the number of functioning nephrons. Drugs predominantly eliminated unchanged in urine, including aminoglycosides, digoxin, metformin and some antibiotics, will accumulate in proportion to the decreases in the GFR. Consequently, these drugs will require a dose adjustment accordingly to the estimated glucose filtration rate (eGFR) or creatinine clearance (CrCl) to prevent drug toxicity. 3. Tubular Secretion. Active tubular secretion by transporters, such as

organic anion transporters (OAT) and organic cation transporters (OCT) is markedly reduced in CKD. Drugs which undergo this form of elimination such as penicillin's, cephalosporins, or metformin will also have diminished clearance and extended half-lives. Tubular Reabsorption: Changes to the processes of tubular reabsorption will depend on urinary pH and urinary flow rate, which will also be altered in renal failure. Acidity (acidosis) or alkaline status (alkalosis) may change the ionization and reabsorption of weak acids and bases and therefore affect systemic drug levels.

3.5 Effect on Drug Half-life and Toxicity

A direct result of the aforementioned changes, is a protracted elimination half-life (t½) of drugs that are renally excreted. For example:

1. The half-life of gentamicin may increase from 2 hours (normal renal function) to over 20 hours in severe chronic kidney disease (CKD) [29].2. Accumulation of metformin can cause lactic acidosis.3. Clearance of digoxin decreases rapidly and the patient needs to have both dose and administration frequency decreased These pharmacokinetic changes can increase the risk of adverse effects, such as hypoglycaemia (insulin, sulfonylureas), metabolic acidosis (metformin), and nephrotoxicity (NSAIDs, aminoglycosides). The patients' polypharmacy, or taking numerous medications, increases their risk of drug-drug interactions and toxicity.

3.6 Clinical Considerations

Pharmacokinetic modifications occurring in renal insufficiency have clinical implications that extend beyond changes in serum drug concentrations [30]. The interaction between renal insufficiency and diabetes creates a potential for further variability in pharmacologic response. As a result, it is necessary to consider patient-specific factors when monitoring the response to pharmacologic therapy based on renal function test results utilizing principles of pharmacokinetics. Seeking eGFR or creatinine clearance routinely provides clinicians an opportunity to quantify the degree of renal impairment and adjust the agent(s) dosing accordingly. If available, therapeutic drug monitoring (TDM) may be warranted for agents narrow therapeutic index agents, such as digoxin, vancomycin, and anti-epileptics70.It is important to note that dosing strategies for agents eliminated primarily by renal excretion versus those eliminated by hepatic pathways but having active metabolites cleared renally, both

require dose adjustments. Understanding how drug elimination occurs is fundamental to establish that neither underdosing nor overdosing occurs.

Fig.3 Pharmacokinetic changes in renal failure

4. Principles of Dose Adjustment in Renal Impairment

Renal adjustment of dose in clinical pharmacotherapy is a vital factor of clinical therapy, especially in diabetic patients who often develop chronic kidney disease (CKD) [31]. With deterioration of renal functions, the pharmacokinetic and pharmacodynamic characteristics of many drugs are highly changed. As such, it is necessary to establish the dose and dose interval so as to ensure efficacy in therapy, as well as to reduce toxicity. This section provides the basis principles, clinical aids and procedures of rational dose adjustments in renal impairment.

4.1 Estimation of Renal Function

The most essential and important thing in the process of drug dose adjustment is proper evaluation of renal function [32]. The gold standard is the direct measurement of the glomerular filtration rate (GFR) with inulin or radio isotopic tracers, which are rather labour-intensive and cannot be used in routine clinical practice. In turn, in order to use eGFR and creatinine clearance (CrCl) as surrogate indicators, estimated GFR (eGFR) and creatinine clearance (CrCl) are commonly used.

a. Serum Creatinine and Its Limitations.

Serum creatinine is the most common procedure that is used to estimate the renal function but has a number of limitations. Several factors can tend to underestimate renal impairment in diabetic patients who have a low muscle mass, liver disease, or

old age [33]. Overestimation on the other hand may occur due to high protein intake or muscle bulk. Therefore, eGFR or CrCl formulas are desirable to be used in a more precise assessment.

b. Cockcroft-Gault Equation

The Cockcroft Gault (CG) formula is still the most common way of deciding on drug dosing:

$$CrCl\ (mL/min) = \frac{(\ 140\ -\ age\ )\ x\ weight\ (kg)\ x\ (\ 0.85\ if\ female\ )}{72\ \text{x serum creatinine (mg/dL)}}$$

The equation gives an estimate of creatinine clearance at ages, sexes, and body weights. It is regularly applied even though it has limitations since the majority of pharmacokinetic dosing recommendations are founded on CrCl.

C. MDRD and CKD-EPI Equations

eGFR standardized to body surface area (1.73m²) is estimated using the Modification of Diet in Renal Disease (MDRD) equation and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [34].MDRD equation is applicable in the staging of CKD but not at close normal GFR values.The CKD-EPI equation is more precise over a wider scope of renal function and is currently suggested by KDIGO and ADA guidelines to be used in clinical settings.

d.Cystatin C-based Estimation

Cystatin C is a low-molecular-weight protein freely filtered by the glomerulus and not influenced by muscle mass or diet which is more accurate as a measure of renal functioning especially in diabetic or elderly groups [35]. Joint creatinine-cystatin C equations increase the precision of marginal cases.

4.2 Classification of Renal Impairment

4.2.1 Renal Impairment Classification

The impaired renal function is normally categorized into levels according to eGFR (mL/min/1.73 m²) [36].

Table 1 Renal Impairment Classification

Stage	Description	eGFR (mL/min/1.73m²)
1	Normal or high	≥90
2	Mild decrease	60–89
3a	Mild to moderate	45–59
3b	Moderate to severe	30–44
4	Severe decrease	15–29
5	Kidney failure (ESRD)	<15

The extent of kidney failure determines the level of dose modification and frequency of observation.

4.3 General Strategies for Dose Modification

Dose adjustment in renal impairment is aimed at maintaining steady-state plasma drug concentrations as in normal subjects, without causing toxicity [37]. It is based on two key strategies:

a. Dose Reduction.This is the reduction in the total dosage but keeping the dose cycle unchanged. It is appropriate where the pharmacodynamic effect of drugs is highly associated with peak plasma concentration like aminoglycosides or antiepileptics.

For example:

$$\text{Adjusted Dose Normal dose } x \ \frac{\text{Patient's CrCl}}{100}$$

Patient's CrCl (100 mL/min is the normal renal functioning)

b. Increase of dosing interval. In this case, the total dose is the same, but the dose-intervals are longer in order to give the drug more time to be eliminated [38]. The method is ideal when using time-dependent drugs such as beta-lactam antibiotics or digoxin.

For example:

$$\text{Adjusted Interval} = \text{Normal Interval x} \quad \frac{100}{\text{Patient's CrCl}}$$

C. Combined Adjustment

Both reduction of dosages and increase in intervals might be necessary in drugs of small therapeutic windows. The best method will be based on the pharmacokinetic and pharmacodynamic properties of the drug [39].

4.4 Loading and Maintenance Doses

Renal impairment does not usually change the loading dose as it is considerably dependent on the volume of distribution, rather than on clearance. Nonetheless, the dosage of maintenance should be adjusted to lower the ability to eliminate [40].

$$\text{Maintenance Dose} = \text{Loading Dose x} = \frac{\text{Patient's Clearance}}{\text{Normal Clearance}}$$

The lack of adapting the maintenance dose may cause accumulation and toxicity especially in the case of some drugs like digoxin, lithium, and some oral hypoglycemics.

4.5 Factors that affect dose Adjustment

4.5.1 A number of patient and drug specific factors contribute to dose change:

1. Renal Dysfunction Degree- eGFR as estimated by eGFR or CrCl [41]. 2. Drug Elimination Pathway - Drugs excreted through the primary pathway, the kidney, need more adaptation compared to drugs excreted through the secondary pathway, the hepatic.3. Therapeutic Index - Drugs with narrow-therapeutic-index (e.g. digoxin, phenytoin, lithium) are drugs, which require careful titration.4. Protein Binding- Plasma protein changes may enhance free drug concentration.5. Dialysis - Removal of drugs in the process of haemodialysis or peritoneal dialysis should be considered. Low molecular weight drugs, low protein binding drugs, and low Vd are more liable to be dialyzable.6. Coexisting Conditions.Diabetes, hepatic dysfunction or heart failure can also have an additional influence on the drug pharmacokinetics.

4.6 Dose Adjustment in Peritoneal Dialysis and Haemodialysis

The issue of administering drugs to dialysis patients is unique.

Water-soluble, low-molecular-weight drugs may be lost in hemodialysis (HD), and must be replaced after dialysis. PD, which is less efficient, has a lower rate of clearance and thus dose modification is not usually as intense. To decide on the necessity of post-dialysis supplementation, clinicians have to consult dialysis-specific drug removal tables. They can be vancomycin, aminoglycosides and beta-lactam antibiotics, that have to be re-dosed following HD.

4.7 Observation and Clinical Analysis.

Dose adjustment is not a single choice but a continuous procedure which is directed by continuous observation of the renal functioning, drug effectiveness as well as toxicity [42].Serum creatinine, BUN, and electrolytes are biochemical markers that are to be assessed regularly.Agents with small safety margin should be monitored using therapeutic drug monitoring (TDM).Direct indicators of drug efficacy are clinical parameters (e.g., blood glucose of insulin, blood pressure of

antihypertensives, etc.).The education of patients is also important, patents are to be advised on adherence, symptoms of toxicity, and the significance of a regular follow-up.

4.8 Clinical Pharmacist role and Guidelines

The clinical pharmacists are essential in the optimization of drug therapy in renal impairment. They give recommendations as to dose adjustments, observe the possibility of drug interaction, and provide compliance with the established guidelines. The standardized structures of renal dosing are provided in such authoritative guidelines as the ones designed by the American Diabetes Association (ADA), Kidney Disease: Improving Global Outcomes (KDIGO), and U.S. FDA. Such guidelines can be integrated into electronic prescribing systems which will play a great role in minimizing the errors that occur during medication [43].

5. Drug Therapy of Renal Failure Diabetes

Kidney Disease: Improving Global Outcomes (KDIGO), and U.S. FDA. Such guidelines can be integrated into electronic prescribing systems which will play a great role in minimizing the errors that occur during medication. With the decline in the state of renal functioning, the insulin metabolism and the pharmacodynamics of the oral antidiabetic agents are considerably altered. The safe and effective glycemic control in this susceptible population therefore is based on the rational choice and dosing of antidiabetic agents [44].

5.1 Pathophysiology of Glycemic Variability in Renal Failure

Renal failure influences glucose homeostasis in a variety of ways. The kidney is involved in gluconeogenesis, insulin degradation and glucose reabsorption and therefore, the impairment of the kidney affects the glucose metabolism. The decreased renal gluconeogenesis lowers the endogenous glucose synthesis whereas the decreased insulin clearance increases the half-life of insulin, which exposes patients to hypoglycemia [45]. In addition, uremic toxins disrupt the process of glucose synthesis in the hepatolysis and glucose uptake to peripheral tissues, making the glycemic control difficult. Due to the co-occurrence of anorexia and malnutrition and changing insulin sensitivity, further variability in blood glucose occurs.

5.2 Insulin Therapy in Chronic Kidney Disease

a. Altered Insulin Pharmacokinetics

Under normal physiology, about 30–40% of circulating insulin is metabolized by the kidneys. In those with advanced CKD, insulin clearance decreases in proportion to the decrease in GFR, increasing insulin half-life and the potential for hypoglycemia. Insulin sensitivity may temporarily improve in early CKD as a result of weight loss and decreased hepatic glucose output, but will decrease later in CKD due to uremic insulin resistance. These opposing forces contribute to the necessity of individualized insulin doses.b. Principles of Insulin Dose Adjustment.Mild to moderate CKD (Stages 1–3): Insulin doses might remain the same or reduce slightly. However, frequent self-monitoring of blood glucose (SMBG) is important to observe trends [46]. Severe CKD (Stage 4–5 or ESRD)- TDD of insulin will likely need to be reduced 25–50% depending on GFR and trends in BG values. Long-acting insulins may accumulate; therefore, pharmacists often recommend shorter-acting insulin products.c.Choice of Insulin Regimen.The standard of care in human insulin preparations has been maintained, but analog insulins might have the benefit of predictability and lessening nocturnal hypoglycemia.The basal-bolus regimens with the insulin glargine or insulin detemir basal insulin, and insulin lispro or aspart prandial insulin are usually adopted.During hemodialysis, glucose excretion during dialysis may cause temporary hypoglycemia insulin pre-dialysis dosage should be decreased by 20-25 percent.CSII pumps could be a better option in some patients.

5.3 Oral Antidiabetic Agents in Renal Failure.

The choice of an effective oral hypoglycemic agent in CKD should be made on the strategy of balancing between efficacy and safety. Most of the agents are renally excreted and their usage should be restricted or avoided because of renal failure [47].

a. Metformin

Metformin is an effective, weight-neutral, and cardiovascular first-line drug in the treatment of type 2 diabetes[48]. Nevertheless, it is mainly excreted intact through the kidney, and its excessive accumulation can be the cause of lactic acidosis, a severe but uncommon complication.eGFR [?]45 mL/min/1.73 m2: Resume normal observation after 3-6 months.eGFR 30-44: Reduce dose by 50 per cent of normal (maximum 1g/day) and do not start therapy.eGFR less than 30: Contraindicated because of high chances of lactic acidosis.Metformin is also not to be used in acute kidney injury (AKI), radiographic contrast tests, or acute illnesses.

b. Sulfonylureas

Sulfonylureas are acting by stimulating pancreatic insulin release although they have high possibility to cause hypoglycemia in renal failure as the effects of active metabolites are long-lasting [49].Glyburide (Glibenclamide): This should be avoided at all costs; it has renally excreted metabolites which build up and lead to long term hypoglycemia.Glipizide: The choice of sulfonylurea in CKD because it contains inactive metabolites, and it is largely metabolized in the liver.Gliclazide: It is also safer comparatively in mild to moderate CKD.The initiation of dose must be conservative with the lowest possible dose level with close supervision of glucose.

C.Meglitinides (Repaglinide, Nateglinide)

These short acting insulin secretagogues are more flexible during and after meals and less associated with hypoglycemia than the sulfonylureas. The drug Repaglinide may be administered in mild to moderate levels of CKD, though there is a gradual introduction of dose. The dose of nateglinide should be reduced in cases of eGFR less than 60 and not less than 30

5.4 Incretin-Based Therapies

a. Dipeptidyl Peptidase-4 (DPP-4) Inhibitor.

DPP-4 inhibitors (eg. sitagliptin, vildagliptin, saxagliptin, linagliptin) increase the actions of endogenous incretin, which stimulates the release of insulin in response to glucose and inhibits glucagon.

Table 2 Incretin-Based Therapies

Drug	**Renal Adjustment**	**Comments**
Sitagliptin	Reduce to 50 mg/day if eGFR 30–50; 25 mg/day if <30	Safe with adjustment
Vildagliptin	Avoid in severe CKD	Mild risk of accumulation
Saxagliptin	Reduce to 2.5 mg/day for eGFR ≤50	May cause fluid retention
Linagliptin	No dose adjustment required	Hepatic clearance predo

The desired agent in the advanced CKD is linagliptin, because of the lack of renal clearance.

b.Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists.Liraglutide, semaglutide, and dulaglutide are agents that enhance the glycemic control and provide renal and cardiovascular protection[50].The majority of GLP-1 analogues are safe in eGFR above 30 mL/min/1.73 m^2. Exenatide must not be used in eGFR less than 30 because of accumulation.GLP-1 RAs can also be utilized to induce weight loss and enhance renal hemodynamics, and thus is a new form of diabetes CKD management.

5.5 Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors

The SGLT2-inhibitors (e.g. empagliflozin, dapagliflozin, canagliflozin) decrease proximal tubule glucose reabsorption, enhancing glycosuria and osmotic diuresis [51]. They have renoprotective and cardioprotective effects in addition to glycemic control, which qualify them as decisive in the contemporary management of diabetes.

Though, when GFR decreases their effectiveness decreases:eGFR [?]60: Complete efficacy and protection of the kidney.eGFR 30-59: The decrease of glycemic effect, but cardiovascular and renal benefits remain preserved [52]; it could be continued according to ADA-KDIGO.eGFR less than 30 Traditionally contraindicated but there is recent evidence that it can be used in some cases to protect renal functions (under specialist direction).The potential side effects are geniturinary infections, loss of volume, and infrequent euglycemic ketoacidosis**.**

5.6 TZDs (thiazolidinediones)

By activating PPAR-γ, pioglitazone and rosiglitazone cause insulin sensitization [53]. In cases of renal failure, these drugs do not require dose adjustments because they are metabolized hepatically. However, their use should be cautious in CKD patients with cardiac comorbidities because of fluid retention and the possibility of heart failure exacerbation.

5.7 Inhibitors of Alpha-Glucosidase

In severe chronic kidney disease (CKD), acarbose and voglibose can build up and cause gastrointestinal intolerance by delaying the intestinal absorption of carbohydrates [54]. When eGFR is less than 30 mL/min/1.73 m2, they are usually avoided.

5.8 Safety Concerns and Contraindications

Table 3 Summary of Safety Concerns and Contraindications

Drug Class	Major Concerns in Renal Failure	Clinical Recommendation	Reference
Metformin	Lactic acidosis	Avoid if eGFR <30	[55]
Sulfonylureas	Severe hypoglycemia	Prefer glipizide/gliclazide	[56]
Insulin	Accumulation, hypoglycemia	Reduce dose 25–50%	[57]
SGLT2 inhibitors	Volume depletion, infections	Continue if eGFR ≥30	[58]
GLP-1 RAs	Nausea, delayed gastric emptying	Avoid exenatide if eGFR <30	[59]
TZDs	Fluid retention, heart failure	Use cautiously	[60]

6. Diabetic Renal Failure: Handling Co-Morbid Conditions

Rarely do renal failure and diabetes mellitus coexist. Multiple comorbidities, such as cardiovascular disease (CVD), dyslipidemia, and hypertension, are common in patients with diabetic kidney disease (DKD). These interconnected disorders raise morbidity and mortality and hasten renal deterioration. Thus, a key element of providing patients with diabetes with renal impairment with holistic care is the thorough management of comorbid conditions.

6.1 Hypertension in Diabetic Nephropathy

a. Epidemiology and Pathophysiology

Hypertension is present in more than 70% of patients with diabetic kidney disease and plays a key role in the progression of nephropathy [61]. Hypertension in diabetic individuals is the result of not only salt sensitivity and sodium retention, but also activation of the renin–angiotensin–aldosterone system (RAAS), increased sympathetic nervous activity, and dysfunction of

arterial endothelium. This constellation results in glomerular hyperfiltration, intraglomerular hypertension, and continued injury to nephrons — the latter contributing to a sort of "double-whammy" that further drives renocerebral dysfunction.

b. Blood Pressure goals and Monitoring

In accordance with the KDIGO (2021) and ADA (2023):

The target BP should usually be <130/80 mmHg with diabetic CKD if well tolerated.Out of office or home BP monitoring is recommended in place of single office measurements to diagnose nocturnal hypertension and possible white-coat effects.

It remains a debate whether to lower aggressively (<120 systolic) due to risk of hypotension particularly in advanced CKD or old age [62].

c. Antihypertensive Agents

i.ACE Inhibitors (ACEI) and Angiotensin Receptor blockers (ARB)

The agents are used as the first-line treatment of diabetic renal disease because they have a dual mechanism of managing BP and decreasing the proteinuria. They block RAAS pathway, thereby reducing intraglomerular pressure, reducing the rate of CKD progression, and cardiovascular protection [63].

Eg. (Enalapril, Lisinopril, Losartan, Valsartan**)**.

Surveillance: creatinine and potassium in the serum should be monitored within 1-2 weeks of starting/increasing dose. Side effects: Hyperkalemia, acute GFR decrease (mostly reversible), and cough (ACEIs). Clinical Note: ACEI + ARB should not be used together because of the likelihood of hyperkalemia and renal dysfunction**.** (ii**)** Calcium Channel Blockers (CCBs**)**They are also good second drug choices if BP targets are missed with ACEI/ARB monotherapy.Dihydropyridines (eg, amlodipine) will lower BP but have little effect on proteinuria.Albuminuria may be decreased with the use of non-dihydropyridines (verapamil, diltiazem as acceptable alternatives when RAAS inhibitors cannot be used.(iii. Beta Blockers**)**Useful in diabetic renal patients with ischaemic heart disease, cardiac failure or tachyarrhythmias.Atenolol and Nadolol are excreted renally with dose adjustment needed [64].Carvedilol and metoprolol are hepatically metabolized and are the drugs of choice for advanced CKD.Potentially precipitates hyperglycemia; monitor blood glucose and adjust accordingly Beta-blockers may obscure signs of hypoglycaemia.(iv. Diuretics**)**Diuretics facilitate the control of volume overload and hypertension in patients with CKD.Thiazide diuretics such as hydrochlorothiazide are effective in mild CKD (eGFR >30)[65].

The use of loop diuretics (such as furosemide, torsemide) is often the best option for treatment of edema in advanced CKD.This combination (loop + thiazide) may also be used for difficult to control hypertension under specialist care.(v.Mineralocorticoid Receptor Antagonists (MRAs)Spironolactone, eplerenone and newer finerenone add further to the reduction of albuminuria offer cardiovascular protection but increase the risk for hyperkaliemia. Finerenone, a nonsteroidal MRA, has demonstrated favorable renal outcomes and reduced risk of hyperkaliemia.

6.2 DIABETIC RENAL FAILURE AND LIPID CONTROL

a. Dyslipidemia Profile in CKD

The modification of lipid metabolism in renal dysfunction results in a specific profile termed uremic dyslipidemia, which consists:Elevated triglycerides,Reduced HDL cholesterol,Normal or mildly ↑LDL with marked increase in small dense particles (more atherogenic).This lipoprotein abnormality contributes to accelerated atherosclerosis and enhances the likelihood of cardiovascular (CV) events the most frequent cause of death in diabetic renal patients.b. Lipid-Lowering Therapy and Statins.(i.)The HMG-CoA Reductase Inhibitors are known as statins. The management of dyslipidemia in diabetic CKD is supported by statins because they have a high cardiovascular risk reduction. Agents: Simvastatin, atorvastatin, and rosuvastatin. Dosing: the majority of statins have no contraindications in CKD, but rosuvastatin will need dose modification (do not exceed 10mg/day in eGFR<30). Evidence: SHARP trial revealed that there was a significant decrease in major

atherosclerotic events with simvastatin-ezetimibe combination in CKD participants. Recommendation: KDIGO suggests statin treatment to all adults [?]50 years with CKD who are not on dialysis, and the younger patients with diabetes and risks. (ii. Fibrates) Fenofibrate and gemifibrozil lower triglycerides but may elevate serum creatinine and enhance statin-associated myopathy in CKD.It is not recommended in moderate to severe CKD (eGFR <30), and should be used with cautions when using in combination.(iii. Ezetimibe and PCSK9 Inhibitors) [66].Ezetimibe blocks cholesterol absorption from the gut and is renally safe.(eg, alirocumab, evolocumab) also provide substantial LDL reduction without a lower dosing threshold in patients with CKD, creating an alternative treatment of refractory dyslipidemia in those with diabetic CKD.

6.3 Antiplatelet and Anticoagulant Therapy

a. Platelet Dysfunction in CKD

CKD is a cause of both hypercoagulable states and uremic platelet disorder, which renders the use of antiplatelet therapy a clinical challenge[67]. Patients with diabetes mellitus are at high thrombotic risk, but renal failure increases bleeding diathesis.

b. Aspirin and Antiplatelet Agents. Unless contraindicated by other conditions, low-dose aspirin (75-150 mg/day) is advised in the secondary prevention of cardiovascular events in diabetic patients with renal failure[68]. Aspirin needs to be tailored in the case of primary prevention, and bleeding risk (e.g., in old age or dialysis patients) should be taken into account. Clopidogrel can be used in aspirin intolerance, and its dosage does not have to be adjusted in CKD. Dual antiplatelet therapy (aspirin + clopidogrel) is indicated in recent coronary stenting or acute coronary syndrome after which close monitoring of bleeding takes place.

c. Anticoagulation.

Warfarin is still an option in more advanced CKD, but will need regular INR monitoring because of changes in protein binding and potential drug interactions[69].Apixaban, rivaroxaban) have limited ESRD data but may be cautiously used at reduced doses in patients with eGFR >15 mL/min.

6.4 Other Co-Morbid Considerations

a. Anemia Management

Erythropoiesis stimulating agents (ESAs) or intravenous iron therapy increase Hg and QOL but should aim at Hb < 11.5 to minimize CV risk. (b) Bone-Mineral Disorders Anemia due to erythropoietin-deficiency and iron-restriction is common among diabetic CKD.Imbalances in calcium phosphate metabolism and vitamin D deficiency are also factors of secondary hyperparathyroidism. Management consists of phosphate binders, calcimimetics and native vitamin D analogs[70]. (c) Lifestyle and Nutritional Modifications.Dietary sodium restriction <2 g/day to help control BP.Protein 0.8 g/kg/day should be supplied to the patient in stages 3–5 CKD (pre-dialysis).Weight reduction, smoking cessation, and exercise are important adjunctive measures to pharmacologic treatment.

6.5 Integrated Therapeutic Approach

Control of diabetic renal failure requires a comprehensive approach involving diabetologists, nephrologists, cardiologists and dietitians.Therapy should be tailored to.The stage of CKD [71],Presence of cardiovascular disease,Tolerance to medications,Patient Compliance and Quality of Life.Scheduled treatment regimens are inferior to patient-based dynamic therapeutic schemes based one regular assessment of renal function, ion metabolism and metabolic status.

7. Clinical Guidelines and Recommendations.

Renal-impaired diabetic patients should be treated according to the set clinical guidelines provided by the leading professional organizations, such as the American Diabetes Association (ADA), kidney disease. [72]Improving Global Outcomes (KDIGO), and the European Association for the Study of Diabetes (EASD). These guidelines focus on a personalized and evidence-based method to maximize the glycemic control and reduce the risks of hypoglycemia and drug toxicity.

7.1 ADA and KDIGO Consensus regarding Diabetes Management in CKD.

The ADA-KDIGO Consensus Report (2022) is a ground breaking collaborative model in the care of diabetic kidney disease (DKD) [72]. The joint recommendations concentrate on five main areas of therapeutic pillars:

7.1.1 Lifestyle and Risk Factor Change.

Strictly advised are weight management, smoking abstinence, and limitation of dietary sodium (<2 g/day). At least 150 minutes per week of moderate-intensity physical exercise are recommended, according to renal condition and cardiovascular tolerance. In non-dialysis CKD, protein consumption ought to be limited to 0.8 g/kg/day to balance between renal and nutritional adequacy.

7.1.2 Glycemic Control

A normal level of HbA1c (7.0) (53 mmol/mol) is suitable in the majority of patients with CKD.Reduced targets (7.5-8.0% can be applied in elderly patients, advanced CKD or subjects of high risk of hypoglycemia [73].Individualization of targets and repeated monitoring are underlined as opposed to set objectives.

7.1.3 Pharmacologic Hierarchy

Pharmacologic Hierarchy The agreement provides a systematic pharmacotherapy course: First-line therapy: Metformin (if eGFR [?]45 mL/min/1.73 m2)[74]. Nephron-cardiovascular protection SGLT2-inhibitors (empagliflozin, dapagliflozin, canagliflozin). Second-line therapy: The use of GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide, etc.) to add to additional glycemic and renal advantages. Third-line options: DPP-4 inhibitors or insulin, depending on the response to them and the state of kidneys**.**

7.1.4 Cardiovascular Risk Management and Blood Pressure.

Target BP: <130/80 mmHg.Preferred agents ACE inhibitors or ARBs, to the greatest dose tolerated.Adjunct treatments: SGLT2 inhibitors and nonsteroidal MRAs (finerenone) as a protection of the kidneys.It is advised that statins should be used in diabetic CKD patients [?]50 years of age regardless of the initial lipid levels [75].

7.1.5 Periodic Surveillance and check-up.

At least once in a year, eGFR and urine albumin-creatinine ratio (UACR) should be evaluated.
The electrolyte and potassium should be monitored upon the initiation of RAAS blockers or MRAs.Thorough cardiovascular examination ECG and lipid profiles are recommended annually.

7.2 The adjustment of Glycemic Targets is based on the specifics of the person being targeted.

The risk of hypoglycemia, comorbidities and life expectancy need to be considered when determining the glycemic targets. Tight control (HbA1c 6.5-7%) is beneficial to younger patients with early CKD [76]. In older patients or patients with advanced chronic kidney disease, moderate levels of control should be used because of decreased renal insulin clearance and an increased likelihood of hypoglycemia. Unlike the HbA1c, time-in-range measurements and continuous glucose monitoring (CGM) are recommended in the management of dialysis patients to enhance accuracy and reduce variability.

7.3 Guidelines Recommendations of Insulin and Drug Dosing.

Table 4 Guidelines Recommendations of Insulin and Drug Dosing

Drug Class	ADA / KDIGO Recommendation	Dose Considerations	References
Metformin	Continue if eGFR ≥45; reduce dose if 30–44; stop if <30	Risk of lactic acidosis	[77]

SGLT2 inhibitors	Start if eGFR ≥30; continue for renal and CV protection even if glycemic benefit wanes	Monitor volume status	[78]
GLP-1 RAs	Recommended if SGLT2 not tolerated or contraindicated	Avoid exenatide if eGFR <30	[79]
DPP-4 inhibitors	Sitagliptin (dose-adjust), Linagliptin (no adjustment)	Preferred in advanced CKD	[80]
Insulin	Dose reduction by 25–50% in advanced CKD	Avoid long-acting accumulation	[81]

This is an organized method that balances both efficacy and safety at CKD stages and comorbid conditions.

7.4 Lipid and Cardiovascular Principles.

According to the KDIGO Lipid Management Guideline (2021) Statin treatment in all diabetic kidney disease patients >50 years (not under dialysis).Statin + Ezetimibe combination[82]: eGFR less than 60 ml/min/1.73m².Fibrates are not contraindicated, but should be used with caution because of myopathy.

7.4.1 The ADA (2024) further advises:

LDL-C less than 70mg/dl: secondary prevention.Unless contraindicated, high-intensity statin therapy (atorvastatin 40-80mg or rosuvastatin 20-40mg).All patients with a history of cardiovascular events or high risk of ASCVD should undergo antiplatelet therapy (low-dose aspirin), but on an individual basis should have bleeding risks [83].

7.5 Blood Pressure and RAAS Inhibition Guidance

Table 5 Blood Pressure and RAAS Inhibition Guidance

Guideline	**Target BP**	**Preferred First-Line Agents**	**Additional Notes**	**References**
KDIGO 2021	<120mmHg systolic (if tolerated)	ACEI or ARB	Avoid dual blockade	[84]
ADA 2023	<130/80 mmHg	ACEI/ARB; add CCB or diuretic as needed	Monitor K^+ and creatinine	[85]
ESH 2023	<130/80 mmHg (younger) / <140/85 (elderly)	ACEI/ARB ± CCB	Encourage home BP monitoring	[86]

Both guidelines emphasize that RAAS inhibition is to be maximized in order to decrease albuminuria and delay CKD progression, as long as the serum potassium is less than 5.5mmol/L.

7.6 Personalized Therapy Methodology.

Individualized or precision therapy is the main idea of diabetes and CKD management in modern times.Treatment must consider [87].Renal disease (eGFR and albuminuria category) stage, Old age, comorbidities, and weakness, Hypoglycemic and polypharmacy risk,Social economic and availability of monitoring resources. Multidisciplinary approach that incorporates the services of diabetologists, nephrologists, cardiologists and dietitians are best to provide the best results. Shared decision making gives patients more power, increases adherence and decreases hospitalization.

Table 6 Monitoring Frequency and Follow-up

Parameter	**Frequency (Minimum)**	**Purpose**	**Reference**
eGFR & UACR	1–4 times per year (based on CKD stage)	Track renal progression	[88]
HbA1c	Every 3 months	Assess glycemic control	[89]
Serum K^+ & Creatinine	Within 1–2 weeks of RAAS/MRA initiation	Detect hyperkalemia	[90]
Lipid Profile	Annually	Cardiovascular risk assessment	[91]
Retinopathy & Neuropathy Screening	Yearly	Prevent microvascular complications	[92]

Multidisciplinary review on a regular basis enables dose adjustment and avoidance of adverse drug reactions on time.

8. Problems and Future Projections.

Although significant progress has been made in the learning of diabetic kidney disease (DKD) and the establishment of renoprotective medications, there are still many clinical challenges remained when managing diabetic patients with renal failure [93]. These issues touch on pharmacologic, clinical, and socioeconomic areas and represent the necessity of continued innovation and personalized care plans.

8.1 Drugs and Polypharmacy:

The patient is undergoing polypharmacy and drug interactions. Polypharmacy using numerous drugs at the same time to treat diabetes, hypertension, dyslipidemia, and cardiovascular disease is one of the greatest obstacles of managing diabetic renal failures. As much as polypharmacy is necessary, it predisposes the risk of: Interaction of drug and drug (e.g., ACEI + potassium-sparing diuretic hyperkalemia), Accumulating nephrotoxicity (NSAIDs,contrast,some antibiotics) and Pill burden compliance problems.The adherence and safety can be improved through regular reviewing of medications, deprescribing multiple agents, and the use of once-a day fixed dose combinations [94].

8.2 Hypoglycemic Risk

Because of decreased insulin clearance, decreased gluconeogenesis, and compromised drug metabolism, hypoglycemia risk increases in renal failure [95].Severe hypoglycemia episodes raise cardiovascular mortality in addition to lowering quality of life. Therefore, when possible, continuous glucose monitoring (CGM) should be used for glucose monitoring, and glycemic targets should be customized. Balancing the best possible glycemic control with the lowest possible risk of hypoglycemia is still difficult, especially for older or dialysis-dependent patients**.**

8.3 Small Therapeutic Index in End-stage CKD

In advanced chronic kidney disease, many antidiabetic medications have limited therapeutic margins [96]. At specific eGFR thresholds, metformin, sulfonylureas, and SGLT2 inhibitors should be used with caution or stopped. Clinicians are frequently forced to rely only on insulin due to this pharmacologic restriction, which carries the risk of unpredictable absorption and hypoglycemia in uremic states. Therefore, there is still a pressing clinical need to develop glucose-lowering medications that are safe for the kidneys.

8.4 Clinical Practice and Guidelines Adherence Variability.

Even with clear ADA-KDIGO guidelines, there is a significant difference in compliance with guidelines across regions and healthcare systems [97]. In resource-restricted environments, their use is restricted by the cost and accessibility of newer treatments like SGLT2 inhibitors, GLP-1 receptor agonists, etc. Rural environments do not provide early intervention because of the absence of nephrology consultation and poor lab monitoring. The process of dealing with these disparities by education, telemedicine, and policy reform is needed to ensure better real-world outcomes.

8.5 New Therapies and Renoprotective Therapies.

In the past years, innovative advances on the treatment of diabetes and CKD have occurred

a. Inhibitors of SGLT2

SGLT2 inhibitors have been shown in large clinical trials such as EMPA-REG OUTCOME, DAPA-CKD, and CREDENCE to be disease modifying agents that, independent of glucose lowering, decrease the progression of CKD, heart failure hospitalization, and cardiovascular death. (b. GLP-1 Receptor Agonists). Semaglutide and liraglutide GLP-1 Ras have extra glucose weight, and cardiovascular advantages. Their contribution to the protection of the kidney is supported by the decreases of albuminuria and the decreases of eGFR[98].(c. Nonsteroidal Mineralocorticoid Receptor (e.g., Finerenone) Antagonists)Finerenone has shown great renal and cardiovascular improvement against DKD patients with less risk of hyperkalemia than spironolactone. The FIDELIO-DKD and the FIGARO-DKD trials represent a new age of cardiorenal medicine. (d. Precision Medicine and Artificial Intelligence). Predictive models based on AI are being created to recognize early kidney failure and personalize medication, as well as adverse drug interactions. Genomic and proteomic biomarkers can be offering precision dosing and optimization of therapy soon.

8.6 Patient-Centered and Multidisciplinary Care.

Diabetic renal failure management is not restricted to pharmacotherapy. The multidisciplinary model of care, which involves the work of diabetologists, nephrologists, dietitians, and clinical pharmacists, contributes to better education of the patient, positive adherence, and a decrease in hospitalization. Self-monitoring and lifestyle change which is a part of patient empowerment, are the most important to the long-term success.The way to go will be to adopt digital health, remote glucose and AI-driven renal risk assessment tools into practice - closing the divide between patients and healthcare professionals [99].

8.7 Research Priorities

Future studies need to be directed towards.Designing insulin analogs that are renal safe in pharmacokinetics [100]. Discussing the gut microbiota modulation as a treatment supplement of DKD. Comparison of the additive renal efficacy of combination therapies (SGLT2i + GLP-1 RA + MRA). Outcome trials in the dialysis and transplant communities which are still underrepresented in existing studies, are long-term. The connection between molecular and clinical interventions will be a key aspect of reducing the global burden of diabetic renal failure through the use of translational research.

9. Conclusion

Diabetic renal failure is one of the most daunting problems in the contemporary clinical medicine that is a combination of the two world epidemics diabetes and chronic kidney disease. The management involves not just rigid glycemic and blood pressure control but also a prudent choice of the drug and its dose change in accordance with the renal functions. In the past ten years, evidence-based guidelines (ADA, KDIGO, EASD) have changed the therapeutic priorities placing the SGLT2 inhibitors, GLP-1 receptor agonists, and the RAAS.blockade as the foundations of renoprotection. Nevertheless, the job of the clinician is not restricted to pharmacology and includes patient education, lifestyle changes and multidisciplinary teamwork.The future developments will probably consist of precision medicine, monitoring guided by biomarkers, and AI-assisted clinical decision-making which will allow detecting and preventing the renal deterioration at an early stage.At the end, the only way to succeed

in the management of diabetic renal failure is to strike a balance between metabolic control and renal safety as each therapeutic choice must be found to prolong, rather than to deteriorate the quality of life.

Conflict of interest

"The authors declare that there is no conflict of interest."

Acknowledgement

"Conceptualization and literature search, final Draft prepared by Jeewanjot Singh."

Funding

This review received no external funding.

Reference

1. Hanifah M, Harahap Y, Purwanto DJ. Determination of 5-Fluorouracil in Dried Blood Spots for Therapeutic Drug Monitoring and Adverse Event Assessment in Breast Cancer Patients. Clin Pharmacol Adv Appl. 2025;17:243–51.

2. Kakar A, Kakar N, Durand A-C, Mouelhi Y, Gentile S. Global Impact of Obesity and Diabetes on the Increase Incidence and Prevalence of Chronic Kidney disease (CKD) and End Stage Renal Disease (ESRD): A Systematic Review. ResearchSquare. 2021;1–17.

3. Ruiz A, DiCristina S. Absorption to Excretion: The Aging Body's Take on Drugs – A Review of Pharmacokinetic Changes and their Impact on Medication Management. Curr Pharmacol Reports. 2025;11:1–13.

4. Thakur AK, Tyagi S, Shekhar N. Comorbid brain disorders associated with diabetes: therapeutic potentials of prebiotics, probiotics and herbal drugs. Transl Med Commun. 2019;4:1–13.

5. Susilawati E, Levita J, Susilawati Y, Sumiwi SA. Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients. Med Sci. 2023;11:1–12.

6. Lou H, Jiang Y, Xu C, Dong ZM, Liu D, Qiao C, et al. Effects of a combination of dyslipidemia and hypertension on the glycemic control of patients with type 2 diabetes mellitus: a cross-sectional study. SAGE Open Med. 2024;12.

7. Chu HY, Jain R, Xie H, Pottinger P, Fredricks DN. Voriconazole therapeutic drug monitoring: Retrospective cohort study of the relationship to clinical outcomes and adverse events. BMC Infect Dis. 2013;13:1–9.

8. Lim CE, Pasternak B, Eliasson B, Ueda P. Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes. Diabetologia. 2025;68:1680–95.

9. Guo L, Yuan J, Cai L, Zhu C, Zheng Y, Yang H, et al. Disease Burden of Gastrointestinal Tumors in China From 1990 to 2021, an Analysis for the Global Burden of Disease Study 2021. J Evid Based Med. 2025;

10. Pereira F, Bolduc C, Melly P, Renggli V. Informal Caregivers in Transitional Hospital-to-Home Care for Older People: Addressing Gaps in Pre-Discharge Collaboration for Enhanced Patient Outcomes. Patient Prefer Adherence . 2025;19:3159–67.

11. Hliel A, Ahmed H, Hasan H. Assessment and prediction of diabetic kidney disease in patients with type 2 diabetes mellitus by using an advanced biomarkers Assessment and prediction of diabetic kidney disease in patients with type 2 diabetes mellitus by using an advanced biomarkers´ y prediccio n Evaluacio n tipo 2 mediante el uso de biomarcadores avanzados. Cirugía Española (English Ed. 2025;45:101330.

12. Mosa OF. Evaluation of SCORED as a diagnostic tool for early detection of chronic kidney disease (CKD) and End-stage

renal disease (ESRD): A hospital-based study Journal of Clinical and Biomedical Sciences Evaluation of SCORED as a diagnostic tool for early detection of chronic kidney disease (CKD) and End - stage renal disease (ESRD): A hospital - based study. 2025;

13. Ratan Y, Rajput A, Pareek A, Pareek A, Singh G. Comprehending the Role of Metabolic and Hemodynamic Factors Alongside Different Signaling Pathways in the Pathogenesis of Diabetic Nephropathy. 2025;

14. Nawale RB, Mourya VK, Bhise SB. Minireview Non-enzymatic glycation of proteins : A cause for complications in diabetes. 2025;43:337–44.

15. Yang Y, Xu G. Update on Pathogenesis of Glomerular Hyper fi ltration in Early Diabetic Kidney Disease. 2022;13:1–11.

16. Viçosa UF De, Marques-rocha L, Samblas M, Milagro FI, Mart JA. Noncoding RNAs , cytokines , and in fl ammation-related diseases. :3595–611.

17. ScienceDirect_articles_30Nov2025_19-09-27.

18. Lennon R, Randles MJ, Humphries MJ. The importance of podocyte adhesion for a healthy glomerulus. 2014;5:1–17.

19. D CMÖM, Ph D, D MLM, D AGM, Ph D. Glomerular Basement Membrane Thickness in Diabetic Kidney Disease. 2020;

20. Shilpasree AS, Patil VS, Revanasiddappa M, Patil VP, Ireshnavar DS. Renal Dysfunction in Prediabetes : Confirmed by Glomerular Hyperfiltration and Albuminuria. 2021;

21. Osman KS, Albakoush AM, Azab AE, Bshina HA, Abdulsalam A. Prevalence of Microalbuminuria among Type2 Diabetes Patients in Zawia City , Western Libya. 2025;9:13–21.

22. Kawtharany H, Jorge A, Azzam M, Bartels CM, Cunha JS, Dequattro K, et al. Renal Replacement Therapy in Lupus Nephritis – Related End-Stage Kidney Disease : A Systematic Review and. 2025;7:1–13.

23. Of I. INSIGHTS-JOURNAL OF HEALTH AND REHABILITATION ELECTROCARDIOGRAPHIC (ECG) ABNORMALITIES IN DIABETIC PATIENTS PRESENTING WITH CHEST PAIN : CORRELATION WITH GLYCEMIC CONTROL AND HEALTH AND REHABILITATION. :131–40.

24. Remita K, Fedhila W, Omar F. Clinical co-management of gouty nephropathy : A bidirectional interface between rheumatology and nephrology. 2025;12.

25. Brassfield J. Natural Bioenhancers in Oncology : Modulation of CYP3A4 and P-glycoprotein to Improve Oral Paclitaxel Absorption. 4.

26. Hirata K, Ikeda T, Watanabe H, Maruyama T, Tanaka M, Tuan V, et al. The Binding of Aripiprazole to Plasma Proteins in Chronic Renal Failure Patients. 2021;

27. Sherman M, Smith C, Rollins H, Fogarty J, Sahi J. Influence of Gender and Ethnicity on Drug Metabolizing Enzymes in Primary Human Hepatocytes. 2009;27560.

28. Chen W, Wang B, Liang S, Wang M, Zheng L, Xu S, et al. Renal clearance of graphene oxide: glomerular filtration or tubular secretion and selective kidney injury association with its lateral dimension. J Nanobiotechnology. 2023;21:1–19.

29. Schlaich MP, Mahfoud F, Böhm M, Narkiewicz K, Ruilope L, Williams B, et al. Renal Denervation in Patients With Moderate to Severe Chronic Kidney Disease. 2025;2252–61.

30. Fang Y-W, Huang H, Jang N, Yen- J-TW, Huang T, Hsien M. Pharmacokinetic study of polymyxin B in healthy subjects and subjects with renal insufficiency. 2024;1–11.

31. Shelke K, Parkhe T, Shinde D. Review Article OPTIMIZING ANTIHYPERTENSIVE THERAPY IN CHRONIC KIDNEY

DISEASE (CKD) PATIENTS : A REVIEW OF DOSE ADJUSTMENTS AND CLINICAL CONSIDERATIONS. 2025;17.

32. Nurdiansyah I, Susilo R, Setyaningsih I, Putri A. DRUG DOSE ADJUSTMENT IN CHRONIC KIDNEY FAILURE. 2025;10:65–72.

33. Dooley MJ, Singh S, Rischin D. Rounding of low serum creatinine levels and consequent impact on accuracy of bedside estimates of renal function in cancer patients. 2004;991–5.

34. Chen L, Guh J, Wu K, Chen Y, Kuo M, Hwang S, et al. Modification of Diet in Renal Disease (MDRD) Study and CKD Epidemiology Collaboration (CKD-EPI) Equations for Taiwanese Adults. 2014;9.

35. Spencer S, Desborough R, Bhandari S. Should Cystatin C eGFR Become Routine Clinical Practice ? 2023;1–11.

36. Kuwatsuru Y, Hirano T, Wakabayashi R, Yumi J, Hideaki I. Changes in renal function over time in outpatients with eGFR ≥ 30 mL / min / 1 . 73 - m 2 : implication for timing of renal function testing before contrast - enhanced CT imaging. Jpn J Radiol. 2023;

37. Sandro C, Yuan G, Lefe G. Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine : A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer ' s Disease. 2016;

38. D YLP, Ab C, Ph P, D FGSP, Rosanna C. Dosing interval strategies for two-dose COVID-19 vaccination in 13 low- and middle-income countries of Europe : health impact modelling and benefit-risk analysis. 2021;

39. Hvarchanova N, Radeva-ilieva M. Using Physiologically Based Pharmacokinetic Models for Assessing Pharmacokinetic Drug – Drug Interactions in Patients with Chronic Heart Failure Taking Narrow Therapeutic Window Drugs. 2025;1–14.

40. ร ู ปแบบการใช ้ และการตรวจต ิ ดตามระด ั บยาแวนโคม ั ยซ ิ นในผ ู ป ้ หญ ่ Vancomycin Use Pattern and Therapeutic Drug Monitoring in Adult Patients.

41. Schini M, Toronjo NPL, Thomas UE, Walsh AKREJS. Evaluation of estimated glomerular function (eGFR) versus creatinine clearance (CrCl) to predict acute kidney injury when using zoledronate for the treatment of osteoporosis. Osteoporos Int. 2021;

42. Kelleci B, Demirkan K. Sürekli Renal Replasman Tedavisinde İlaç Kullanımı ve Doz Ayarlaması İçin Kullanılan Elektronik İlaç Bilgi Kaynaklarının Karşılaştırılması. 2018;9:7–11.

43. Saho M. The Role of Electronic-Based System in Minimizing Medication Error. 2025;6:285–7.

44. Willey CJ, Andrade SE, Cohen J, Fuller JC, Gurwitz JH. Polypharmacy With Oral Antidiabetic Agents : 2002;12:435–40.

45. González-casimiro CM, Cámara-torres P, Merino B, Astudillo AM, Fuente MA De, Ramírez CM, et al. Decreased expression of insulin- degrading enzyme increases gluconeogenesis and glucose production in cultured hepatocytes administered with glucagon. 2025;1–13.

46. Utami H, Id R, Anggriani Y, Lepeska M, Beran D, Ewen M. Availability , price and affordability of insulin , delivery devices and self-monitoring blood glucose devices in Indonesia. 2024;1–17.

47. Implication C, Brismar TB, Geisel D, Kartalis N, Madrazo BL, Hedman HP, et al. Oral Manganese Chloride Tetrahydrate : A Novel Magnetic Resonance Liver Imaging Agent for Patients With Renal Impairment. 2024;59.

48. Bahardoust M, Hadaegh F, Mehrabi Y, Delpisheh A. Medication time of metformin and sulfonylureas and incidence of cardiovascular diseases and mortality in type 2 diabetes : a pooled cohort analysis. 2025;1–14.

49. Chakraborty T. Uses for Tolbutamide Type 2 Diabetes Mellitus by Tapamoy Chakraborty Pharmacodynamics.

50. Aa K, Review AFN, Peptide G-L, Agonists R, Sci M. هژاودیلک اهـ Review of the Mechanism and Function of Glucagon-Like

Peptide 1 (GLP-1) and GLP-1 Receptor Agonists in the Improvement of Type 2 Diabetes. 2023;1:222–39.

51. Lee Y, Im D. SGLT2 Inhibitors Empagliflozin and Canagliflozin Ameliorate Allergic Asthma Responses in Mice. 2024;

52. Iftekhar MF. Empagliflozin in the Real World : Strengthening Heart Failure Care in Pakistan. 2025;5–7.

53. Pachiappan S, Samundi SP, Pachiappan S, Theivendren P, Pavadai P, Chandrasekar S. EVALUATION OF AMELIORATIVE EFFICACY OF CARBOPLATIN WITH PIOGLITAZONE THROUGH ADIPONECTIN AUGMENTATION BY ACTIVATING PPAR-γ IN HIGH-FAT DIET-INDUCED OVARIAN CANCER IN MICE. 49.

54. Hayeeawaema F, Sermwittayawong N, Tipbunjong C. Live and heat-killed Leuconostoc mesenteroides counteract the gastrointestinal dysfunction in chronic kidney disease mice through intestinal environment modulation. 2025;1–24.

55. Salem SR, Beeraka NM, Roaeid RB, Huria TR, Sr S, Nm B, et al. Use of metformin according to renal function in patients with type II diabetes. 2021;4:1–6.

56. Dimakos J, Cui Y, Platt RW, Renoux C, Filion KB. Pharmacologic Heterogeneity and Risk of Severe Hypoglycemia with Concomitant Use of Sulfonylureas and DPP- - Based Cohort Study. 2023;114.

57. Miyaue K. Exogenous Insulin Antibody Syndrome : An Overlooked Cause of Severe Hypoglycemia and Insulin Resistance in a Patient With Type 2 Diabetes Treated With Insulin. 2025;1–3.

58. Mcgovern AP, Hogg M, Shields BM, Sattar NA, Holman RR, Pearson ER, et al. Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. 2020;11–3.

59. Chang MG, Ripoll JG, Lopez E, Krishnan K, Bittner EA. A Scoping Review of GLP-1 Receptor Agonists : Are They Associated with Increased Gastric Contents , Regurgitation , and Aspiration Events ? 2024;1–41.

60. Karunarathna I, Jayawardana A, Fernando C, Vidanagama USG, Ekanayake UPN, Hapuarachchi TMB, et al. Thiazolidinediones in Type 2 Diabetes Mellitus : indications , Monitoring , and the Care. 2025;

61. Ghannadzadeh R. Association of cardiovascular risk factors with diabetic kidney disease severity in the Iranian population.

62. Pressão N De, Crônica R, Revisão U, Hugo V, Pereira D. BLOOD PRESSURE LEVELS AND THE PROGRESSION OF CHRONIC KIDNEY DISEASE : A SYSTEMATIC REVIEW. 2025;243–53.

63. Shihas M, Nasir M, Shaik H, Khan F, Sarfraz M, Tareg R, et al. Renoprotective Effects of RAAS Inhibitors in Patients with Diabetic Nephropathy : A Comprehensive Meta-Analysis of Randomized Controlled Trials. 2025;3:57–63.

64. Brennan MT, Harmouch KM, Basit J, Alraies MC. Beta-Blocker Usage in Patients With Heart Failure With Reduced Ejection Fraction During Acute Decompensated Heart Failure Hospitalizations. 2024;1–6.

65. Unit N. Department of Clinical Pharmacy and Pharmacy Administration, University of Maiduguri, Maiduguri, Nigeria 2 Department of Medicine, Nephrology Unit, University of Maiduguri Teaching Hospital, Maiduguri, Nigeria. 2024;23:70–7.

66. Tang H, Li X, Wang F, Liu H, Zhang X, Liu B, et al. Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease. 2025;1–10.

67. Xiong J, He T, Yu Z, Yang K, Chen F, Cheng J, et al. Antiplatelet therapy for the prevention of atherosclerosis in chronic kidney disease (ALTAS-CKD) patients : study protocol for a randomized clinical trial. 2021;1–11.

68. 3,5,6# ,. 2024;

69. Naseralallah L, Nasrallah D, Koraysh S, Al-qudimat AR. Real-World Evaluation of the Interaction Between Rifampicin and Warfarin : A Retrospective Observational Study. 2025;2025:1–8.

70. Sowa-kućma M. Secondary hyperparathyroidism in chronic kidney disease : pathomechanism and current treatment possibilities. 2023;490–8.

71. Schnell O, Almandoz J, Anderson L, Barnard-kelly K, Battelino T, Blüher M, et al. CVOT summit report 2024 : new cardiovascular , kidney , and metabolic outcomes. 2025;

72. Tsai K, Chen S, Chou C, Tzeng T, Lee Y, Chen M. Quality of care and prescription patterns among patients with diabetic kidney disease — a large-scale cohort study from Taiwanese clinics. 2022;1–15.

73. Hern K, Ch G. Impact of HbA1c Reduction on Major Kidney Outcomes in Type 2 Diabetes With Poor Glycemic Control and Advanced CKD. 2025;2025.

74. Zhang Y, Luo J, Li B, Xu J, Yu H, Chen N. Cardio - renal protective effect and safety of sodium - glucose cotransporter 2 inhibitors for chronic kidney disease patients with eGFR < 60 mL / min / 1 . 73 m2 : a systematic review and meta - analysis. BMC Nephrol. 2024;

75. Adnan M, Bibi T, Hakim A, Mobeen H. Correlation of Creatinine and Urea Levels in Diabetic Patients of Lahore with Chronic Kidney Disease (CKD). 2025;III:6–11.

76. Lv Q, Shen J, Miao L, Ye B, Schepers C. Early Combination Therapy with Linagliptin and Metformin in People with Type 2 Diabetes Improves Glycemic Control to HbA1c £ 6 . 5 % without Increasing Hypoglycemia : Pooled Analysis of Two Randomized Clinical Trials. Diabetes Ther. 2020;

77. Ashraf S, Upreti P, Karki S, Khan M, Nasr R. Metformin-Associated Lactic Acidosis : A Case Report and Review Case Presentation. 2022;14:8–11.

78. Inhibitors WS, Receptor G-, Fletcher RA, Arnott C, Costa JDO, Falster MO, et al. Estimated Lifetime Cardiovascular , Kidney , and Diabetes and Albuminuria. 2024;450–62.

79. Hiddo JL, Daniel J, John PH, Brown E, Heerspink HJL, Cuthbertson DJ, et al. Therapeutics SGLT2 inhibitors and GLP-1 receptor agonists : established and emerging indications. Lancet. 2021;398:262–76.

80. Jairoun AA, Ping CC, Ibrahim B. Pharmacotherapeutic considerations and treatment patterns of antihyperglycemic agents for diabetic nephropathy : a review of the literature. 2023;12058–69.

81. Peng ZY, Yang CT, Lin WH, Yao WY, Ou HT, Kuo S. Chronic kidney outcomes associated with GLP - 1 receptor agonists versus long - acting insulins among type 2 diabetes patients requiring intensive glycemic control : a nationwide cohort study. Cardiovasc Diabetol. 2023;1–12.

82. Silva VC, Muenz D, Wong MMY, Mccullough K, Charytan D. International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care : is it time to review guideline recommendations ? 2023;1–10.

83. Caterina R De, Aimo A, Ridker PM. Aspirin Therapy for Primary Prevention : The Case for Continuing Prescribing to Patients at High Cardiovascular Risk — A Review cardiovascular events. 2020;

84. International K. KDIGO 2021 CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF BLOOD PRESSURE. 2021;1–87.

85. Morris D. Management of hypertension. 2024;1–7.

86. Branch H, Society G, Association BH, Diseases G, Hua Q, Fan L. 2023 Guideline for the management of hypertension in the elderly population in China. 2024;21:589–630.

87. Orvostudományok E, Iskola D. A folyadék-túlterhelés , a hemodialízis vérnyerési modalitás és az effektív kezelési idő fontossága vesepótló terápiák során Doktori tézisek Semmelweis Egyetem. 2017;

88. Neuen BL, Weldegiorgis M, Herrington WG, Ohkuma T, Smith M. Changes in GFR and Albuminuria in Routine Clinical Practice and the Risk of Kidney Disease Progression. Am J Kidney Dis. 2021;XX:1–12.

89. Care C. Immediate Feedback of HbA 1 c L e v e l s. 1999;22:1–5.

90. Finerenone in DKD : Could it be a Game-changer ? S10. 4:84883.

91. Orozco-beltran D, Gil-guillen VF, Redon J, Martin- JM, Pallares-carratala V, Navarro-perez J, et al. Lipid profile , cardiovascular disease and mortality in a Mediterranean high-risk population : The ESCARVAL-RISK study. 2017;1–20.

92. Goldney J, Sargeant JA, Davies MJ. Incretins and microvascular complications of diabetes : neuropathy , nephropathy , retinopathy and microangiopathy. Diabetologia. 2023;66:1832–45.

93. Yu C, Shi W, Chen E, Qiu Y, Gao L. Clinical characteristics and prognostic analysis of patients with type 2 diabetic kidney disease and non-diabetic kidney disease. 2025;1–10.

94. Sarzani R, Laureti G, Gezzi A, Spannella F, Giulietti F. Single-pill fixed-dose drug combinations to reduce blood pressure : the right pill for the right patient. 2022;1–19.

95. Shreen S, Ali MW, Khan MA, Majeed SA, Misbah M, Haq U. INNOSC Theranostics and Pharmacological Sciences Drug-induced hypoglycemia in a patient with Type 2 diabetes and renal impairment : A case report. 2025;X:5–10.

96. Code L. Population PK / PD model to evaluate the effect of uremia on the pharmacokinetics of evogliptin 약동학 / 약력학 모델을 이용한 요독증의 evogliptin 약동학에 대한 영향 평가.

97. Eder S, Leierer J, Kerschbaum J, Rosivall L, Wiecek A, Zeeuw D De, et al. Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries. 2019;

98. Cheng T, Wang X, Han Y, Hao J, Hu H, Hao L. The level of serum albumin is associated with renal prognosis and renal function decline in patients with chronic kidney disease. BMC Nephrol. 2023;1–17.

99. Articles O. Artificial intelligence in nephrology : revolutionizing diagnosis , treatment , and patient care. 2024;13:213–9.

100. Mhaske A, Shukla S, Ahirwar K, Singh KK, Shukla R. Receptor - Assisted Nanotherapeutics for Overcoming the Blood – Brain. Mol Neurobiol. 2024;61:8702–38.